Immunovant, Inc.
IMVT
$13.84
-$1.38-9.07%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 7.10% | -1.79% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -1.24% | 22.76% | |||
| Operating Income | 1.24% | -22.76% | |||
| Income Before Tax | -1.77% | -25.23% | |||
| Income Tax Expenses | 94.87% | 1.30% | |||
| Earnings from Continuing Operations | -1.84% | -25.21% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -1.84% | -25.21% | |||
| EBIT | 1.24% | -22.76% | |||
| EBITDA | 1.25% | -22.77% | |||
| EPS Basic | -1.52% | -24.87% | |||
| Normalized Basic EPS | -1.46% | -24.91% | |||
| EPS Diluted | -1.52% | -24.87% | |||
| Normalized Diluted EPS | -1.46% | -24.91% | |||
| Average Basic Shares Outstanding | 0.31% | 0.26% | |||
| Average Diluted Shares Outstanding | 0.31% | 0.26% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||